As Biomarin Pharmaceutical Inc. unveiled a data analysis comparing the efficacy of Kyndrisa (drisapersen) in similar patients across three randomized studies, the FDA let fly with briefing documents for Tuesday's meeting of the Peripheral and Central Nervous System (PCNS) Drugs Advisory Committee (adcom).